Sana Biotechnology Announces the Acceptance of Four

SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL.

Late-breaking poster details:

Title:Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
Session Title:Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date:Wednesday, April 19, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 35
Abstract Number:LB311


Poster details:

Title:Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2734


Title:Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome
Session Category:Experimental and Molecular Therapeutics
Session Title:Gene and Vector-based Therapy
Session Date:Monday, April 17, 2023
Session Time:1:30 p.m. - 5:00 p.m. ET
Location:Poster Section 16
Abstract Number:2735


Title:Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Session Category:Immunology
Session Title:CAR T-cell Therapy 2
Session Date:Tuesday, April 18, 2023
Session Time:9:00 a.m. - 12:30 p.m. ET
Location:Poster Section 23
Abstract Number:4091


Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR Online Itinerary Planner located here: https://www.abstractsonline.com/pp8/#!/10828. Late-breaking abstract text will be posted to the AACR Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.

About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester. For more information about Sana Biotechnology, please visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for the Company’s participation at the 2023 American Association for Cancer Research Annual Meeting; expectations for the Company’s presentations at such meeting, including the content of such presentations; and expectations for the publication of abstracts. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 2, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com


Sana Biotechnology Announces the Acceptance of Four

TIN LIÊN QUAN

Tango Therapeutics to Highlight Preclinical Data on

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster...

Mablink Bioscience to Present Promising Preclinical Data

Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

Molecular Partners to Present at SVB Leerink Global

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...

REE Automotive, Ltd. Announces Date for Fourth Quarter 2022

TEL-AVIV, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- REE Automotive, Ltd. (NASDAQ: REE) (“REE” or the “Company”), an automotive technology company and...

THỦ THUẬT HAY

Windows 8 tăng đến 2,7% thị phần trên thị trường hệ điều hành

Hệ điều hành mới đã tăng nhẹ trong tháng hai từ 2,3% của tháng một, nhưng nó vẫn còn ở vị trí thứ tư sau ba sau hệ điều hành cũng củaMicrosoft: Windows 7, Windows XP và Windows Vista.

Troll bạn bè bằng cách tạo virus "giả" trên Notepad

Tại sao không thử cách troll bạn bè của mình bằng “virus”, thử tạo một loại virus giả sau đó gửi cho bạn bè của mình nhỉ. Chắc chắn bạn bè của bạn sẽ phải “hét ầm” lên khi biết máy tính của họ nhiễm “virus giả”.

Hướng dẫn đăng, chia sẻ video TikTok lên Facebook

Nếu sử dụng song song Facebook cùng với TikTok, bạn có thể đăng và chia sẻ video TikTok lên Facebook để nhanh chóng tăng view - tăng tương tác cho tài khoản của mình.

Thunderbird - Ngăn chặn tải những tệp tin dung lượng lớn

Hưỡng dẫn cấu hình hòm thư Thunderbird ngăn chặn tải file lưu trữ quá lớn

Đây là cách đăng nhập nhiều tài khoản Instagram trên cùng một thiết bị

Việc đăng nhập nhiều tài khoản Instagram trên cùng một thiết bị giờ đây đã dễ dàng hơn rất nhiều. Bạn hoàn toàn có thể thực hiện ngay trên máy tính hoặc điện thoại.

ĐÁNH GIÁ NHANH

Đánh giá hiệu năng và thời lượng pin Xiaomi Mi Note 3: có mạnh như kỳ vọng?

So với hai mẫu smartphone cao cấp hiện tại của Xiaomi là Mi Mix 2 và Mi 6 thì Xiaomi Mi Note 3 ít được nhắc đến hơn.

Trên tay Samsung W22 5G – Smartphone màn hình gập xịn sò hơn cả Galaxy Z Fold3 5G 5G

Samsung W22 5G chỉnh là phiên bản đổi tên của Samsung Galaxy Z Fold3 5G nhưng xin sò hơn rất nhiều. Tuy chỉ có một vài thay đổi nhỏ về ngoại hình nhưng khi cầm trên tay Samsung W22 5G lại đem tới một đẳng cấp hoàn toàn